Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q2 2020 · 10-Q
Revenue$2.00B$2.00B−23.9% vs Q2 2019 Net Income-$147.00M-$147.00MN/M vs Q2 2019 EPS Diluted-$0.11-$0.11N/M vs Q2 2019 Gross Profit$1,212,000,000−35.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$269,000,000−7.9% Free Cash Flowderived$201,000,000±0.0% Margins · derivedGross margin60.5%−10.7 pt vs Q2 2019
Operating margin-3.5%−18.1 pt vs Q2 2019
Net margin-7.3%−13.2 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 5, 2020 · 36 d after period end